Problem

Graph Therapeutics addresses the translational gap in inflammation and immunology drug discovery. Immune and inflammatory diseases affect hundreds of millions of people, but conventional discovery methods rely on simplified preclinical models and static biological snapshots that do not capture the dynamic complexity of human immune systems. The resulting high clinical failure rates create billion-dollar losses for drug developers while leaving patients waiting for effective therapies.

Its initial “killer” use case is improving target discovery and validation in sterile inflammation and related immune-mediated diseases, where disease biology is especially networked and patient-specific. By testing therapeutic hypotheses against real patient biology before clinical trials, Graph aims to reduce the risk that an apparently promising mechanism fails when exposed to human disease.

Product / Service

Graph offers a lab-in-the-loop precision-immunology platform rather than a conventional standalone software product. It captures the dynamic behavior of live patient immune cells, applies ex vivo perturbations, collects functional and multimodal data, and uses machine learning and active experimental design to decode disease mechanisms, patient variation, and likely therapeutic responses. The resulting functional disease manifold is intended to show how cells actually respond to intervention, not merely what their genomes might theoretically permit.

The platform is being used to advance Graph’s own internal therapeutic programs, while also creating a basis for strategic partnerships and potential out-licensing. Its benefit is to front-load clinical development: targets and biological hypotheses can be validated in clinically relevant human samples before significant capital is committed, potentially improving target quality, reducing failure rates, shortening discovery timelines, and producing more precise medicines.

Market

Graph competes in the AI-enabled techbio and precision-immunology market, specifically at the intersection of patient-derived functional biology, multi-omics, target discovery, and drug development for inflammatory and immune-mediated disease. Adjacent competitors and comparables identified for the company include Tempus, Generate Biomedicines, and Immunai; Immunai is particularly close in its use of immune-system mapping and partnerships with biopharmaceutical companies, although the companies’ platforms and commercial strategies are not identical. Graph has described the broader opportunity across related inflammation and immunology indications as exceeding $257 billion by 2032.

Graph is an early-stage, privately funded biotech with meaningful development traction but no publicly disclosed revenue or paying-customer figures in the materials reviewed. In June 2026 it reported more than $10 million in cumulative equity and non-dilutive funding, including a new $5 million investment from Daphni, and said its platform had been substantially de-risked and validated across clinically relevant models. It is advancing internal discovery programs across multiple indications and has announced research collaborations with the Botnar Institute of Immune Engineering and Parse Biosciences, suggesting a pre-commercial or early commercialization stage rather than an established revenue business.